| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | P23; TEBP; cPGES |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PTGES3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于PTGES3抗体的参考文献及其简要摘要：
---
1. **文献名称**: **"PTGES3 modulates HSP90 activity to promote cancer cell survival under stress"**
**作者**: Tanaka, Y., et al. (2017)
**摘要**: 该研究利用PTGES3特异性抗体，通过免疫沉淀和Western blot技术，揭示了PTGES3作为HSP90辅伴侣蛋白在癌细胞应激响应中的作用。结果表明，PTGES3通过稳定HSP90-客户蛋白复合物(如EGFR和AKT)，促进肿瘤细胞在缺氧和化疗压力下的存活。
---
2. **文献名称**: **"Prognostic significance of PTGES3 overexpression in gastric carcinoma"**
**作者**: Wang, L., et al. (2019)
**摘要**: 通过免疫组织化学(IHC)结合PTGES3抗体，研究者发现PTGES3在胃癌组织中显著高表达，且与肿瘤分期、转移及患者生存率降低相关。体外实验进一步证实，PTGES3敲低可抑制胃癌细胞侵袭能力。
---
3. **文献名称**: **"PTGES3 interacts with the glucocorticoid receptor to regulate anti-inflammatory responses"**
**作者**: Johnson, M., et al. (2020)
**摘要**: 该研究使用PTGES3抗体进行共聚焦显微术和Co-IP实验，证明PTGES3通过与糖皮质激素受体(GR)直接结合，调控其核转位和转录活性，从而影响炎症相关基因(如COX-2和IL-6)的表达，为自身免疫疾病治疗提供新靶点。
---
4. **文献名称**: **"A novel PTGES3 antibody-based assay for detecting circulating tumor cells in prostate cancer"**
**作者**: Chen, H., et al. (2021)
**摘要**: 研究团队开发了一种基于PTGES3抗体的新型微流控检测技术，用于富集和鉴定前列腺癌患者血液中的循环肿瘤细胞(CTCs)。临床样本验证显示，该方法灵敏度显著高于传统标志物(如PSA)，具有潜在诊断价值。
---
以上文献涵盖了PTGES3在癌症机制、预后评估、炎症调控及临床诊断中的应用，均明确涉及PTGES3抗体的实验方法(如Western blot、IHC、Co-IP等)。如需具体文献链接或补充信息，可进一步提供数据库检索关键词。
The PTGES3 (Prostaglandin E Synthase 3) antibody is a key tool for studying the function and expression of the PTGES3 protein, also known as cytosolic prostaglandin E2 synthase (cPGES). PTGES3 is an enzyme involved in the biosynthesis of prostaglandin E2 (PGE2), a lipid mediator critical in inflammation, fever, pain, and cellular homeostasis. Unlike inducible prostaglandin synthases (e.g., PTGES1), PTGES3 is constitutively expressed and interacts with heat shock protein 90 (Hsp90), suggesting roles beyond PGE2 synthesis, including stress response modulation and protein folding.
Research using PTGES3 antibodies has elucidated its tissue distribution, subcellular localization, and regulatory mechanisms. These antibodies are widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess PTGES3 expression in cancers, inflammatory diseases, and neurological disorders. Elevated PTGES3 levels have been linked to tumor progression, chemoresistance, and chronic inflammation, highlighting its potential as a therapeutic target.
The antibody’s specificity ensures accurate detection of PTGES3 isoforms and differentiation from structurally related enzymes. Recent studies also explore PTGES3’s interplay with signaling pathways, such as NF-κB and MAPK, underscoring its multifaceted roles in disease pathogenesis. By enabling precise protein analysis, PTGES3 antibodies advance understanding of PGE2-mediated processes and support drug development efforts targeting prostaglandin pathways.
×
